ReviewCurrent osteoporosis reports2016
Advanced Glycation End Products, Diabetes, and Bone Strength.
Review in Current osteoporosis reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
121 citing papers in PubMed, 2 syntheses or guidelines pooled it, 197 citations in OpenAlex.
- Trabecular bone score in adults with type 1 diabetes: a meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024Pooled it
- Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.Frontiers in endocrinology · 2021Pooled it
- Skeletal health in adolescents with poorly controlled type 1 diabetes: results from a randomized controlled trial.BMJ open diabetes research & care · 2025Trial
- Trial
- Pentosidine Is Associated With Cortical Bone Geometry and Insulin Resistance in Otherwise Healthy Children.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019Trial
- Comparison of Bone Microarchitecture and Clinical Biomarkers between Diabetic and Non-Diabetic Postmenopausal Osteoporotic Women.Journal of bone metabolism · 2026Article
- Spatiotemporal immunomodulation with programmable biomaterials to promote musculoskeletal tissue regeneration.Bioactive materials · 2026Review
- Chronic kidney disease: from mineral dysregulation to bone and cardiovascular disease.Journal of endocrinological investigation · 2026Review
- Collagen-Related Viscoelasticity as a Metric for Fracture Assessment in Cortical Bone.Annals of biomedical engineering · 2026Article
- Surgical Treatment of Pathologic Spinal Fractures in Osteoporosis: Two Clinical Cases.Korean journal of neurotrauma · 2026Article
- Type 2 Diabetes Modulates Mesenchymal Stem Cell Response to Advanced Glycation End Products and N-Acetylcysteine Antioxidant Effect.Pharmaceutics · 2026Article
- Genetic and pharmacologic modulation of RAGE rescues the diabetes-mediated impairments to bone at multiple length scales.bioRxiv : the preprint server for biology · 2026Article
- Femora from adults with type 1 or type 2 diabetes have lower bone strength and smaller hip geometry.JBMR plus · 2026Article
- Denosumab's Role in Reducing Type 2 Diabetes Risk and Improving Glycaemic Control in Osteoporotic Patients - A Meta-analysis.Malaysian orthopaedic journal · 2026Article
- Sarcopenia in Aging: Pathogenesis, Diagnosis, and Emerging Therapeutic Frontiers.Molecular imaging and biology · 2026Review
- The contested association between MASLD and osteoporosis: a narrative review of heterogeneous evidence and modifying factors.Archives of osteoporosis · 2026Review
- Biomaterial regulation of excessive inflammation restores osteoimmune homeostasis in diabetic bone regeneration.Regenerative biomaterials · 2026Review
- Cellular and molecular mechanisms of diabetes-mediated disc degeneration.Frontiers in endocrinology · 2026Review
- Investigating the research trajectory and future trends in type 2 diabetes mellitus and aging: a bibliometric analysis from 2009 to 2025 based on big data.Frontiers in aging · 2026Review
- Interorgan Communications in Skeletal Pathophysiology: From Molecular Pathways to Multidisciplinary Therapies.Research (Washington, D.C.) · 2026Review
61 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic patients have a higher fracture risk than expected by their bone mineral density (BMD). Poor bone quality is the most suitable and explainable cause for the elevated fracture risk in this population. Advanced glycation end products (AGEs), which are diverse compounds generated via a non-enzymatic reaction between reducing sugars and amine residues, physically affect the properties of the bone material, one of a component of bone quality, through their accumulation in the bone collagen fibers. On the other hand, these compounds biologically act as agonists for these receptors for AGEs (RAGE) and suppress bone metabolism. The concentrations of AGEs and endogenous secretory RAGE, which acts as a "decoy receptor" that inhibits the AGEs-RAGE signaling axis, are associated with fracture risk in a BMD-independent manner. AGEs are closely associated with the pathogenesis of this unique clinical manifestation through physical and biological mechanisms in patients with diabetes mellitus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.